A new article has been published by the magazine "Wirtschaftswoche Gründe" about ATRIVA. You can read it here...
Funds to advance antiviral lead product ATR-002 into clinical trials
Tübingen (Germany), January 3, 2019 – Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therap
The next generation of antiviral therapies: After successfully passing an important preclinical development milestone for the lead compound ATR-002 in summer 2017, Atriva Therapeutics GmbH adds a seasoned biopharmaceutical executive, Dr. Christi